| Literature DB >> 18390992 |
Philippe A Cassier1, Sawsan Abou-Amara-Olivieri, Pascal Artru, Marie-George Lapalus, Jean-Paul Riou, Catherine Lombard-Bohas.
Abstract
Ectopic adrenocorticotropin secretion (EAS) remains a therapeutic challenge whenever the tumor responsible for the syndrome is not amenable to curative resection. Two cases of EAS related to metastatic foregut-derived endocrine carcinomas led us to use mifepristone, an antagonist of both progesterone and glucocorticoids. Mifepristone clearly improved skin lesions and diabetes associated with hypercorticism. The beneficial effect lasted for about 10 months. In both cases, recurrent hypertension and hypokalemia eventually required adrenalectomy.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18390992 DOI： 10.1530/EJE-07-0792
Source DB: PubMed Journal: Eur J Endocrinol ISSN： 0804-4643 Impact factor: 6.664